Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Embryonic stem cell therapy - Regenerative Patch Technologies

Next Previous
Search
Drug Profile

Embryonic stem cell therapy - Regenerative Patch Technologies

Alternative Names: CPCB-RPE1; CPCB-RPE1 IMPLANT; hESC-RPE Synthetic Substrate Patch

Latest Information Update: 08 Feb 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator California Institute of Technology/CalTech; University of California, Santa Barbara; University of Southern California
  • Developer Regenerative Patch Technologies
  • Class Pluripotent stem cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Dry age-related macular degeneration

Most Recent Events

  • 04 Feb 2022 Efficacy data from phase I/II trial in Dry age related macular degeneration released by Regenerative Patch Technologies
  • 07 Jul 2021 Regenerative Patch Technologies completes enrollment in phase I/II clinical trials in Dry Age-related macular degeneration in USA (Intraocular) prior to July 2021 (NCT02590692)
  • 28 Jun 2021 Efficacy data from phase I/II trial in Dry age related macular degeneration released by Regenerative Patch Technologies

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top